- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03644563
Men and Women Offering Understanding of Throat HPV (MOUTH)
Impacting the Oral HPV Continuum: MOUTH Study (Men and Women Offering Understanding of Throat HPV)
Study Overview
Status
Conditions
Detailed Description
This study will provide one of the first estimates of long-term oral HPV natural history, and the effect of biologic and behavioral risk factors, including HIV, on this natural history. Phase 1 of the study will screen approximately 1500 people for oncogenic oral HPV biomarkers. Phase 2 of the study will follow only those subjects with oncogenic oral HPV infection and/or HPV serum oncogene antibodies from Phase 1 (and those previously identified as having oncogenic oral HPV infection in a previous study) with annual follow-up for oncogenic oral HPV persistence.
Understanding persistent oncogenic oral HPV infection is the focus of this study. Understanding which factors drive oral HPV infection to become persistent or progress to malignancy is critical to determine who is at high risk for oropharyngeal cancer and may benefit from screening and prevention. It is presumed that persistent oncogenic oral HPV infections are necessary for progression to HPV-OPC.
The study is led by Dr. Amber D'Souza and Dr Carole Fakhry (Johns Hopkins) and participants are being enrolled in Baltimore MD (Johns Hopkins) and in New York (Mt. Sinai).
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Participants in the Phase 1 Screening
Inclusion criteria:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- 18 and older (enrollment at most sites will be restricted to 30 and older since this demographic has the highest prevalence of infection; however, individuals and/or partners of someone with an HPV-related cancer, for example, are at increased risk so will be enrolled in the larger age range).
- Willing to be contacted to arrange follow-up visits, if determined to be eligible for phase 2
- Ability to understand and the willingness to sign a written informed consent document
In addition, individuals must meet at least one of the following criteria:
- Male, aged 30 and older, with 2 or more lifetime oral sex
- History of anal or genital dysplasia or cancer
- Partners of someone with an HPV-related cancer (HPV-positive OPC, anal cancer or genital cancer)
- Known oncogenic HPV-positive biomarker from prior studies or testing, regardless of number of partners.
Exclusion criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Presence of medical or psychiatric condition affecting ability to give voluntary, informed consent.
- Participants who do not speak English cannot enroll because the consent and study survey are only available in English. However, if there is a hearing, literacy or minor fluency issue and the participant requests assistance from a family member or the study coordinator, this individual may still enroll and receive this assistance to ensure they fully hear and understand everything being asked.
- History of head and neck cancer
Participants in the Phase 2 Follow-Up
Inclusion criteria:
- Oncogenic oral HPV infection and/or HPV serum oncogenic antibodies detected in phase 1
- Willingness to complete annual follow up visits
Exclusion criteria:
• Unable to complete annual follow up visits
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
---|
Follow-up
Those subjects with oncogenic oral HPV infection and/or HPV oncogene serum antibodies from screening.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Oncogenic oral HPV infection present or absent in oral rinse sample
Time Frame: Baseline to end of four year follow-up and data abstraction/linkage.
|
To explore the effects of biologic (microbiome, oral immune response, biologic sex) risk factors for oncogenic oral HPV persistence
|
Baseline to end of four year follow-up and data abstraction/linkage.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HPV16 E6 antibodies present or absent in serum sample
Time Frame: Baseline to end of four year follow-up and data abstraction/linkage.
|
To explore whether E6 and E7 seropositivity (to HPV16 or any oncogenic HPV) are markers for oncogenic oral HPV persistence among high-risk groups
|
Baseline to end of four year follow-up and data abstraction/linkage.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Amber D'Souza, PhD, Bloomberg Johns Hopkins School of Public Health
Publications and helpful links
General Publications
- D'Souza G, Clemens G, Troy T, Castillo RG, Struijk L, Waterboer T, Bender N, Pierorazio PM, Best SR, Strickler H, Wiley DJ, Haddad RI, Posner M, Fakhry C. Evaluating the Utility and Prevalence of HPV Biomarkers in Oral Rinses and Serology for HPV-related Oropharyngeal Cancer. Cancer Prev Res (Phila). 2019 Oct;12(10):689-700. doi: 10.1158/1940-6207.CAPR-19-0185. Epub 2019 Aug 16.
- D'Souza G, Tewari SR, Troy T, Waterboer T, Struijk L, Castillo R, Wright H, Shen M, Miles B, Johansson M, Robbins HA, Fakhry C. Prevalence of oral and blood oncogenic human papillomavirus biomarkers among an enriched screening population: Baseline results of the MOUTH study. Cancer. 2023 Aug 1;129(15):2373-2384. doi: 10.1002/cncr.34783. Epub 2023 Apr 9.
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Pharyngeal Neoplasms
- Otorhinolaryngologic Neoplasms
- Head and Neck Neoplasms
- Pharyngeal Diseases
- Stomatognathic Diseases
- Otorhinolaryngologic Diseases
- Neoplasms, Squamous Cell
- Oropharyngeal Neoplasms
- Papilloma
Other Study ID Numbers
- IRB00119537
- R35DE026631 (U.S. NIH Grant/Contract)
- IRB00007636 (Other Identifier: JHSPH IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oropharyngeal Cancer
-
Wake Forest University Health SciencesTerminatedHead and Neck Cancer | Stage I Laryngeal Cancer | Stage II Laryngeal Cancer | Stage I Hypopharyngeal Cancer | Stage I Oropharyngeal Cancer | Stage II Hypopharyngeal Cancer | Stage II Oropharyngeal Cancer | Stage III Hypopharyngeal Cancer | Stage III Laryngeal Cancer | Stage III Oropharyngeal Cancer | Stage... and other conditionsUnited States
-
Lisette NixonStanford University; University of Leipzig; AdventHealth; UNICANCER; Princess Alexandra...RecruitingHuman Papillomavirus (HPV)-Positive Oropharyngeal CancerGermany, United Kingdom, United States, Australia, France
-
University of FloridaTerminatedOropharyngeal CancersUnited States
-
M.D. Anderson Cancer CenterRecruitingOropharyngeal CarcinomaUnited States
-
Shanghai Jiao Tong University School of MedicineFudan University; Tongji University; Second Military Medical UniversityCompletedOral Cancer | Locally Advanced Malignant Neoplasm | Oropharyngeal CarcinomaChina
-
NexImmune Inc.Not yet recruitingHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Oropharyngeal Cancer | Human Papilloma Virus | Head and Neck Cancer Metastatic | HPV-Related Squamous Cell Carcinoma | Oropharyngeal Cancer, Metastatic | HPV-Related Mucosal Head and Neck Squamous... and other conditions
-
NRG OncologyNational Cancer Institute (NCI)Active, not recruitingTongue Carcinoma | Stage IVA Oropharyngeal Squamous Cell Carcinoma | Stage IVB Oropharyngeal Squamous Cell Carcinoma | Stage IVC Oropharyngeal Squamous Cell Carcinoma | Stage III Oropharyngeal Squamous Cell CarcinomaUnited States, Canada, Saudi Arabia, Ireland
-
Shanghai Jiao Tong University School of MedicineFudan University; Tongji University; Second Military Medical UniversityCompletedOral Cancer | Effects of Chemotherapy | Locally Advanced Malignant Neoplasm | Oropharyngeal CarcinomaChina
-
National Cancer Institute (NCI)CompletedLip and Oral Cavity Cancer | Oropharyngeal Cancer | Tongue Cancer | Stage 0 Lip and Oral Cavity Cancer | Stage 0 Oropharyngeal CancerUnited States
-
Aalborg University HospitalRecruiting